Bioventus (NASDAQ:BVS) Cut to Buy at Wall Street Zen

Key Points

• Wall Street Zen downgraded Bioventus from “strong buy” to “buy.” Overall analyst sentiment remains “Moderate Buy,” with five Buy ratings and one Hold rating and a consensus price target of $16.60.
• Other analyst views were mixed: Canaccord lowered its target from $19 to $18 while keeping a Buy rating, and Weiss Ratings moved its view from Buy to Hold.
• Bioventus reported quarterly EPS of $0.17, in line with consensus, and revenue of $142.44 million. Analysts expect full-year EPS of $0.78.

Bioventus (NASDAQ:BVS - Get Free Report) was downgraded by analysts at Wall Street Zen from a "strong-buy" rating to a "buy" rating in a report released on Saturday, Wall Street Zen reports.

BVS has been the subject of several other research reports. Cantor Fitzgerald reaffirmed an "overweight" rating and set a $15.00 price objective on shares of Bioventus in a research note on Monday, August 17th. Craig Hallum reissued a "buy" rating and set a $18.00 price target on shares of Bioventus in a research report on Thursday, August 6th. Canaccord Genuity Group reduced their target price on Bioventus from $19.00 to $18.00 and set a "buy" rating for the company in a research note on Tuesday. Weiss Ratings cut Bioventus from a "buy (b-)" rating to a "hold (c+)" rating in a research note on Wednesday. Finally, Barrington Research set a $18.00 price objective on Bioventus in a report on Thursday, August 6th. Five analysts have rated the stock with a Buy rating and one has assigned a Hold rating to the company. According to MarketBeat, the company has a consensus rating of "Moderate Buy" and a consensus price target of $16.60.

Bioventus Stock Down 0.7%

Shares of Bioventus stock opened at $10.61 on Friday. The company has a market capitalization of $892.19 million, a P/E ratio of 13.26, a price-to-earnings-growth ratio of 1.68 and a beta of 0.66. The company has a debt-to-equity ratio of 0.83, a current ratio of 1.69 and a quick ratio of 1.17. The business has a 50-day moving average of $13.44 and a two-hundred day moving average of $10.97. Bioventus has a 1 year low of $6.47 and a 1 year high of $15.89.

Bioventus (NASDAQ:BVS - Get Free Report) last posted its quarterly earnings data on Monday, November 2nd. The company reported $0.17 EPS for the quarter, meeting the consensus estimate of $0.17. The business had revenue of $142.44 million for the quarter. Bioventus had a return on equity of 27.52% and a net margin of 9.78%. As a group, equities analysts predict that Bioventus will post 0.78 EPS for the current year.

Institutional Investors Weigh In On Bioventus

A number of institutional investors have recently modified their holdings of the company. Covestor Ltd boosted its holdings in shares of Bioventus by 25.6% in the third quarter. Covestor Ltd now owns 5,808 shares of the company's stock valued at $79,000 after acquiring an additional 1,182 shares during the period. Quantum Financial Partners LLC raised its position in shares of Bioventus by 11.8% during the third quarter. Quantum Financial Partners LLC now owns 14,200 shares of the company's stock worth $194,000 after purchasing an additional 1,500 shares during the period. Signaturefd LLC increased its holdings in Bioventus by 2,809.1% in the third quarter. Signaturefd LLC now owns 1,920 shares of the company's stock worth $26,000 after buying an additional 1,854 shares during the last quarter. USA Financial Formulas bought a new stake in Bioventus in the 3rd quarter valued at $42,000. Finally, Allspring Global Investments Holdings LLC boosted its stake in Bioventus by 4.1% in the third quarter. Allspring Global Investments Holdings LLC now owns 85,874 shares of the company's stock worth $1,170,000 after purchasing an additional 3,367 shares in the last quarter. 62.94% of the stock is owned by institutional investors and hedge funds.

About Bioventus

Bioventus Inc is a medical device and biologics company focused on developing and commercializing products that support bone healing, joint health and surgical recovery. Its portfolio is designed to help healthcare professionals treat musculoskeletal conditions and improve patient outcomes through noninvasive therapies, injectable products and biologic solutions.

The company's offerings include bone stimulation systems such as EXOGEN, which is used to support fracture healing, as well as injectable osteoarthritis treatments including DUROLANE and GELSYN-3.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.